LB Pharmaceuticals Inc Common Stock

NASDAQ: LBRX · Healthcare · Biotechnology

PublicHQ New York, NY · New YorkCIK 0001691082Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 69DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$25.2M

Employees

as of 2026-08-10

Market cap

$1.4B

as of 2026-08-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$25.2M-$25.2M2025

Total assets$312.9M$312.9M2025

Liabilities$11.6M$11.6M2025

Equity$301.3M$301.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is LB Pharmaceuticals Inc Common Stock’s financial profile?

LB Pharmaceuticals Inc Common Stock earned -$25.2M in FY2025 net income.

Peers · Healthcare

First Tracks Biotherapeutics Inc——ArriVent BioPharma, Inc.——ORIC Pharmaceuticals, Inc.——Avalyn Pharma Inc. Common Stock——Vor Biopharma Inc.——Aktis Oncology, Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOHeather D. Turner

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York, NY

ExchangeNASDAQ: LBRX

Employees35

IPO date2025-09-11

Latest filings

8-K2026-08-11 10-Q2026-08-11 8-K2026-07-29 8-K2026-07-22 8-K2026-06-10 8-K2026-06-09 8-K2026-05-12 10-Q2026-05-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.